Glucocorticoid resistance - What is known?

Current Opinion in Pharmacology

Volumn 2, Issue 6, 2002, Pages 723-729

  Norman, Michael ^a   Hearing, Stephen D ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLYCOPROTEIN P; RNA POLYMERASE; TRANSCRIPTION FACTOR;

AUTOIMMUNE DISEASE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESISTANCE; GENE CONTROL; GENE EXPRESSION; HUMAN; HYPERGLYCEMIA; INFLAMMATION; LYMPHOID CELL; LYMPHOPROLIFERATIVE DISEASE; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; GENE EXPRESSION REGULATION; METABOLISM;

DRUG RESISTANCE; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HUMANS; MOLECULAR CHAPERONES; RECEPTOR CROSS-TALK; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION;

EID: 0036906076     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(02)00232-1     Document Type: Review

References (56)

1. Cheung J, Smith DF: Molecular chaperone interactions with steroid receptors: an update. Mol Endocrinol 2000, 14:939-946.
2. Widen C, Zilliacus J, Gustafsson JA, Wikstrom AC: Glucocorticoid receptor interaction with 14-3-3 and Raf-1, a proposed mechanism for cross-talk of two signal transduction pathways. J Biol Chem 2000, 275:39296-39301.
3. Croxtall JD, Choudhury Q, Flower RJ: Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br J Pharmacol 2000, 130:289-298.
4. Doucas V, Shi Y, Miyamoto S, West A, Verma I, Evans RM: Cytoplasmic catalytic subunit of protein kinase A mediates cross-repression by NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA 2000, 97:11893-11898.
5. Gonzalez MV, Jimenez B, Berciano MT, Gonzalez-Sancho JM, Caelles C, Lafarga M, Munoz A: Glucocorticoids antagonize AP-1 by inhibiting the activation/phosphorylation of JNK without affecting its subcellular distribution. J Cell Biol 2000, 150:1199-1208.
6. Maniatis T, Reed R: An extensive network of coupling among gene expression machines. Nature 2002, 416:499-506.
7. McKenna NJ, O'Malley BW: Minireview: nuclear receptor coactivators-an update. Endocrinology 2002, 143:2461-2465.
8. Jenkins BD, Pullen CB, Darimont BD: Novel glucocorticoid receptor coactivator effector mechanisms. Trends Endocrinol Metab 2001, 12:122-126.
9. Chan HM, La Thangue NB: p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 2001, 114:2363-2373.
10. Szapary D, Huang Y, Simons SS Jr: Opposing effects of corepressor and coactivators in determining the dose-response curve of agonists, and residual agonist activity of antagonists, for glucocorticoid receptor-regulated gene expression. Mol Endocrinol 1999, 13:2108-2121.
11. Karin M: New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell 1998, 93:487-490.
12. Reichardt HM, Tuckermann JP, Gottlicher M, Vujic M, Weih F, Angel P, Herrlich P, Schutz G: Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J 2001, 20:7168-7173.
13. van Schaardenburg D, Valkema R, Dijkmans BA, Papapoulos S, Zwinderman AH, Han KH, Pauwels EK, Breedveld FC: Prednisone treatment of elderly-onset rheumatoid arthritis. Disease activity and bone mass in comparison with chloroquine treatment. Arthritis Rheum 1995, 38:334-342.
14. Seki M, Ushiyama C, Seta N, Abe K, Fukazawa T, Asakawa J, Takasaki Y, Hashimoto H: Apoptosis of lymphocytes induced by glucocorticoids and relationship to therapeutic efficacy in patients with systemic lupus erythematosus. Arthritis Rheum 1998, 41:823-830.
15. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, Jewell DP: Predicting outcome in severe ulcerative colitis. Gut 1996, 38:905-910.
16. Langhoff E, Ladefoged J, Jakobsen BK, Platz P, Ryder LP, Svejgaard A, Thaysen JH: Recipient lymphocyte sensitivity to methylprednisolone affects cadaver kidney graft survival. Lancet 1986, 1:1296-1297.
17. Carmichael J, Paterson IC, Diaz P, Crompton GK, Kay AB, Grant IW: Corticosteroid resistance in chronic asthma. BMJ 1981, 282:1419-1422.
18. Hearing SD, Norman M, Smyth C, Foy C, Dayan CM: Wide variation in lymphocyte steroid sensitivity among healthy human volunteers. J Clin Endocrinol Metab 1999, 84:4149-4154.
19. Gratsias Y, Moutsatsou P, Chrysanthopoulou G, Tsagarakis S, Thalassinos N, Sekeris CE: Diurnal changes in glucocorticoid sensitivity in human peripheral blood samples. Steroids 2000, 65:851-856.
20. Choi YI, Jeon SH, Jang J, Han S, Kim JK, Chung H, Lee HW, Chung HY, Park SD, Seong RH: Notch1 confers a resistance to glucocorticoid-induced apoptosis on developing thymocytes by down-regulating SRG3 expression. Proc Natl Acad Sci USA 2001, 98:10267-10272.
21. Gaynon PS, Carrel AL: Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia. Adv Exp Med Biol 1999, 457:593-605.
22. Kralli A, Yamamoto KR: An FK506-sensitive transporter selectively decreases intracellular levels and potency of steroid hormones. J Biol Chem 1996, 271:17152-17156.
23. Gruol DJ, Bourgeois S: Expression of the mdr1 P-glycoprotein gene: a mechanism of escape from glucocorticoid-induced apoptosis. Biochem Cell Biol 1994, 72:561-571.
24. Sandeep TC, Walker BR: Pathophysiology of modulation of local glucocorticoid levels by 11beta-hydroxysteroid dehydrogenases. Trends Endocrinol Metab 2001, 12:446-453.
25. Cooper MS, Bujalska I, Rabbitt E, Walker EA, Bland R, Sheppard MC, Hewison M, Stewart PM: Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res 2001, 16:1037-1044.
26. Rook G, Baker R, Walker B, Honour J, Jessop D, Hernandez-Pando R, Arriaga K, Shaw R, Zumla A, Lightman S: Local regulation of glucocorticoid activity in sites of inflammation. Insights from the study of tuberculosis. Ann New York Acad Sci 2000, 917:913-922.
27. Kang KI, Meng X, Devin-Leclerc J, Bouhouche I, Chadli A, Cadepond F, Baulieu EE, Catelli MG: The molecular chaperone Hsp90 can negatively regulate the activity of a glucocorticosteroid-dependent promoter. Proc Natl Acad Sci USA 1999, 96:1439-1444.
28. Kullmann M, Schneikert J, Moll J, Heck S, Zeiner M, Gehring U, Cato AC: RAP46 is a negative regulator of glucocorticoid receptor action and hormone-induced apoptosis. J Biol Chem 1998, 273:14620-14625.
29. Freeman BC, Yamamoto KR: Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 2002, 296:2232-2235.
30. Ramdas J, Liu W, Harmon JM: Glucocorticoid-induced cell death requires autoinduction of glucocorticoid receptor expression in human leukemic T cells. Cancer Res 1999, 59:1378-1385.
31. Chapman MS, Askew DJ, Kuscuoglu U, Miesfeld RL: Transcriptional control of steroid-regulated apoptosis in murine thymoma cells. Mol Endocrinol 1996, 10:967-978.
32. Kam JC, Szefler SJ, Surs W, Sher ER, Leung DY: Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol 1993, 151:3460-3466.
33. Franchimont D, Martens H, Hagelstein MT, Louis E, Dewe W, Chrousos GP, Belaiche J, Geenen V: Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J Clin Endocrinol Metab 1999, 84:2834-2839.
34. Wallace AD, Cidlowski JA: Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J Biol Chem 2001, 276:42714-42721.
35. Kaul S, Blackford JA Jr, Chen J, Ogryzko VV, Simons SS Jr.: Properties of the glucocorticoid modulatory element binding proteins GMEB-1 and -2: potential new modifiers of glucocorticoid receptor transactivation and members of the family of KDWK proteins. Mol Endocrinol 2000, 14:1010-1027.
36. Melvin VS, Roemer SC, Churchill ME, Edwards DP: The C-terminal extension (CTE) of the nuclear hormone receptor DNA binding domain determines interactions and functional response to the HMGB-1/-2 co-regulatory proteins. J Biol Chem 2002, 277:25115-25124.
37. Lamberts SW: Hereditary glucocorticoid resistance. Ann Endocrinol (Paris) 2001, 62:164-167.
38. Hillmann AG, Ramdas J, Multanen K, Norman MR, Harmon JM: Glucocorticoid receptor gene mutations in leukemic cells acquired in vitro and in vivo. Cancer Res 2000, 60:2056-2062.
39. Yudt MR, Cidlowski JA: The glucocorticoid receptor: coding a diversity of proteins and responses through a single gene. Mol Endocrinol 2002, 16:1719-1726.
40. Webster JC, Oakley RH, Jewell CM, Cidlowski JA: Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance. Proc Natl Acad Sci USA 2001, 98:6865-6870.
41. Carlstedt-Duke J: Glucocorticoid receptor beta: view II. Trends Endocrinol Metab 1999, 10:339-342.
42. Rivers C, Levy A, Hancock J, Lightman S, Norman M: Insertion of an amino acid in the DNA-binding domain of the glucocorticoid receptor as a result of alternative splicing. J Clin Endocrinol Metab 1999, 84:4283-4286.
43. Medh RD, Saeed MF, Johnson BH, Thompson EB: Resistance of human leukemic CEM-C1 cells is overcome by synergism between glucocorticoid and protein kinase A pathways: correlation with c-Myc suppression. Cancer Res 1998, 58:3684-3693.
44. Wang Z, Frederick J, Garabedian MJ: Deciphering the phosphorylation code of the glucocorticoid receptor in vivo. J Biol Chem 2002, 277:26573-26580.
45. Jamieson CA, Yamamoto KR: Crosstalk pathway for inhibition of glucocorticoid-induced apoptosis by T cell receptor signaling. Proc Natl Acad Sci USA 2000, 97:7319-7324.
46. Rogatsky I, Logan SK, Garabedian MJ: Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase. Proc Natl Acad Sci USA 1998, 95:2050-2055.
47. Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM: p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002, 109:649-657.
48. Galigniana MD, Piwien-Pilipuk G, Assreuy J: Inhibition of glucocorticoid receptor binding by nitric oxide. Mol Pharmacol 1999, 55:317-323.
49. Yang-Yen HF, Chambard JC, Sun YL, Smeal T, Schmidt TJ, Drouin J, Karin M: Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 1990, 62:1205-1215.
50. Ray A, Prefontaine KE: Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA 1994, 91:752-756.
51. Adcock IM, Lane SJ, Brown CR, Lee TH, Barnes PJ: Abnormal glucocorticoid receptor-activator protein 1 interaction in steroidresistant asthma. J Exp Med 1995, 182:1951-1958.
52. Stocklin E, Wissler M, Gouilleux F, Groner B: Functional interactions between Stat5 and the glucocorticoid receptor. Nature 1996, 383:726-728.
53. Biola A, Lefebvre P, Perrin-Wolff M, Sturm M, Bertoglio J, Pallardy M: Interleukin-2 inhibits glucocorticoid receptor transcriptional activity through a mechanism involving STAT5 (signal transducer and activator of transcription 5) but not AP-1. Mol Endocrinol 2001, 15:1062-1076.
54. Nissen RM, Yamamoto KR: The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 2000, 14:2314-2329.
55. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin SC, Heyman RA, Rose DW, Glass CK, Rosenfeld MG: A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996, 85:403-414.
56. Hermanson O, Glass CK, Rosenfeld MG: Nuclear receptor coregulators: multiple modes of modification. Trends Endocrinol Metab 2002, 13:55-60.